INVITATION: Presentation of Full-year 2018 Results of Molecular Partners AG Dienstag, 29. Januar 2019 - 17:49
INVITATION
Molecular Partners AG: Full-year 2018 Results
Thursday, February 07, 2019, 2:00pm (CET) – Presentation for Media, Analysts and Investors
Molecular Partners AG cordially invites you to participate in the presentation of the company’s preliminary unaudited key financials for the full-year 2018 as well as a related corporate update which will take place as follows:
Date: Thursday, February 07, 2019
Time: 2:00pm CET (1:00pm GMT, 8:00am EST)
Location: Molecular Partners AG, Wagistr. 14, 5th floor, 8952 Schlieren (directions)
Please indicate if you would like to attend the presentation by completing and returning the registration form by Monday, February 04, 2019.
The presentation and the press release will be available on www.molecularpartners.com from 7:00am (CET) on Thursday, February 07, 2019.
The full audited Annual Report 2018 of the company is expected to be published on March 15, 2019.
Dial-in facilities and an audio webcast will be available for those who are unable to attend the event.
Dial-ins for the conference call:
Switzerland / Europe +41 (0) 58 310 5000
UK +44 (0) 203 059 5862
US +1 (1) 631 570 5613
Please dial-in approximately 10 minutes before the start of the presentation in order to register. Participants will have the opportunity to ask questions after the presentation.
An audio webcast of the FY18 results presentation will be accessible, both live and as a replay, on www.molecularpartners.com, along with the accompanying presentation slides. Please note that there will be no facility to ask questions via the webcast.
For further details, please contact:
Thomas Schneckenburger, IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 44 755 5728
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company that is developing a new class of therapies known as DARPin® therapeutics. The company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.